Sourcing Exosomes in Massachusetts
Licensed Massachusetts practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with lot traceability on every vial and a certificate of analysis issued for every lot and provided on request. Massachusetts buyers need their own professional license and NPI; the non-resident pharmacy and wholesale druggist licenses the Board of Registration in Pharmacy issues sit with the entity that ships into the state rather than with the purchasing practice.
Two Massachusetts points are worth settling early. The state’s 2005 regenerative medicine act governs research institutions rather than clinical practice, so there is no stem cell practice statute to read exosomes into or out of. And the state reaches practice ownership through clinic licensure: a medical spa that is not wholly owned and controlled by its practitioners is licensed by the Department of Public Health as a clinic.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Massachusetts? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 11 September 2026 |
Ordering from Massachusetts
ExaVeyra ships to licensed practices in all 50 states, Massachusetts included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase. What changes state to state is how the state regulates who performs a procedure and how the practice itself is licensed, while federal law governs the product itself.
What your practice provides
- An active Massachusetts professional license in good standing, verifiable through the Board of Registration in Medicine, the Board of Registration in Nursing or the Board of Registration of Physician Assistants.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Massachusetts Sales Tax Resale Certificate (Form ST-4) under 830 CMR 64H.8.1 if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Massachusetts licenses out-of-state shippers through the Board of Registration in Pharmacy. M.G.L. c. 112, § 39J directs the board to license non-resident pharmacies that ship, mail, sell or dispense medications in the commonwealth, and provides that no pharmacy operating outside the state may ship, sell or dispense drug preparations in Massachusetts unless they were produced in a pharmacy holding a non-resident license. Section 36B requires a wholesale druggist license, issued per location and renewed annually, of anyone engaged in the wholesale drug business, and 247 CMR 7.00 implements the federal Prescription Drug Marketing Act’s rule that a wholesale distributor of prescription drugs be licensed in each state where it distributes. Section 39G adds a retail sterile compounding pharmacy license, held to current USP standards and inspected before renewal, for pharmacies that compound sterile preparations. Separately, the Department of Public Health treats every prescription drug as a controlled substance for registration purposes under M.G.L. c. 94C, and its published policy is that a distributor outside Massachusetts whose only in-state activity is direct delivery to a registered entity does not need a Massachusetts controlled substances registration. Each license sits with the supplier, not with the purchasing practice.
M.G.L. c. 112, §§ 36B, 39G, 39J; 247 CMR 6.00, 7.00 · Massachusetts Board of Registration in Pharmacy
Massachusetts regenerative-medicine law
Massachusetts has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Massachusetts did legislate on regenerative medicine, and the act is easy to mistake for a practice law. Chapter 27 of the Acts of 2005 created M.G.L. c. 111L, which permits research and clinical applications involving embryonic, placental, umbilical cord and adult stem cells at institutions holding a certificate of registration from the Department of Public Health, with institutional review board approval of protocols, and prohibits human reproductive cloning. It regulates research infrastructure rather than the delivery of services in a practice, so a Massachusetts practice adding a service line finds its rules in the Board of Registration in Medicine’s regulations, the nursing and physician assistant statutes, and the Department of Public Health’s clinic licensure law.
How this applies to exosomes
Massachusetts has no statute that authorizes or requires a disclosure for stem cell services in a practice, and its 2005 regenerative medicine act concerns registered research institutions, so there is no state definition to read exosomes into or out of. Exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. The state-level questions a Massachusetts practice actually faces are whether it needs a clinic license under M.G.L. c. 111, §§ 51 and 52, and who may perform which procedure under the medical, nursing and physician assistant statutes. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with lot documentation and a certificate of analysis for every lot.
Who can handle product in a Massachusetts practice
Massachusetts spreads the rules across three boards rather than one statute. Physician delegation to a physician assistant runs on the § 9E supervision standard; nursing practice runs on orders and on the nursing board’s advisory rulings; and a nurse practitioner with independent practice authority under § 80E orders within nursing scope on their own. On top of the practice acts sits clinic licensure: unless the entity is wholly practitioner-owned and controlled, the Department of Public Health licenses it as a clinic and inspects it against 105 CMR 140.000.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Board of Registration in Medicine perform medical acts within their scope and are the source of delegation to physician assistants and, through orders, to nurses. The Department of Public Health’s medical spa advisory lists the procedures it treats as medical services that must be performed by or under the direction or supervision of a medical practitioner. |
| NP / APRN | Nurse practitioners gain independent practice authority under M.G.L. c. 112, § 80E after not less than two years of supervised practice following certification, and may then prescribe and order tests and therapeutics without the supervisory guidelines that apply before that point. Before the two years, a nurse practitioner prescribes under guidelines agreed with a supervising physician or a supervising nurse practitioner who holds independent authority. |
| PA | Physician assistants perform medical services under the supervision of a registered physician under M.G.L. c. 112, § 9E. The statute describes that supervision as continuous while not requiring the supervising physician’s personal presence, and leaves the scope of delegated services to the supervising physician’s judgment of the assistant’s training and experience. |
| RN | Registered nurses and licensed practical nurses perform cosmetic and dermatologic procedures within the Board of Registration in Nursing’s Advisory Ruling 1301, which the Board publishes among its practice rulings and which covers injectables, soft tissue fillers, chemical solutions and non-ablative light and laser devices. As the ruling describes the line, medical diagnosis and the selection of the medication, solution, device or device setting sit outside the scope of a nurse who is not an APRN with prescriptive authority, so an RN works to an order from a practitioner who may prescribe. |
Good faith examination
Massachusetts does not use the phrase “good faith examination” as a statutory term. The functional requirement follows from the scope rules: a practitioner who may diagnose and prescribe, meaning a physician, a physician assistant under supervision or a nurse practitioner within § 80E, evaluates the patient and issues the order, and a registered nurse carries out the order without selecting the medication, device or setting. Confirm current expectations with the Board of Registration in Medicine and the Board of Registration in Nursing.
Ownership and clinic licensing
Massachusetts reaches practice ownership through clinic licensure rather than a corporate practice statute. Under M.G.L. c. 111, § 51 the Department of Public Health licenses clinics, and § 52 defines a clinic as any entity, however organized, maintained to provide ambulatory medical services, while exempting a solo or group practice wholly owned and controlled by its practitioners that does not use the words clinic, institute or dispensary in its name. The Department’s 2013 medical spa advisory applies that rule directly: an establishment offering laser, light or radiofrequency devices, chemical peels, soft tissue fillers, botulinum toxin, sclerotherapy or any procedure using a biologic or synthetic material is providing medical services and is subject to clinic licensure under 105 CMR 140.000 unless it is wholly owned and controlled by the practitioners providing them. Structure the entity with Massachusetts counsel before opening.
Cold chain into Massachusetts
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Massachusetts order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Boston | Suffolk | Highest concentration of dermatology, aesthetic and concierge practices in the state. |
| Cambridge | Middlesex | Longevity and research-adjacent practices around the university corridor. |
| Newton and Wellesley | Middlesex and Norfolk | Suburban aesthetic and concierge market west of the city. |
| Worcester | Worcester | Central Massachusetts hub with a broad clinical mix. |
| Springfield | Hampden | Western Massachusetts market serving the Pioneer Valley. |
| Cape Cod | Barnstable | Seasonal aesthetic and concierge practices with a year-round core. |
- Massachusetts orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
Practice types we supply in Massachusetts
Massachusetts licensing and verification
Board of Registration in Medicine
Licenses physicians and regulates the practice of medicine.
Board of Registration of Physician Assistants
A separate board licenses physician assistants in Massachusetts.
Board of Registration in Nursing
Licenses RNs, LPNs and APRNs, and publishes the advisory rulings on cosmetic procedures.
Board of Registration in Pharmacy
Licenses non-resident pharmacies under § 39J and wholesale druggists under § 36B.
Department of Public Health, clinic licensure (105 CMR 140.000)
Licenses a medical spa as a clinic unless it is wholly owned and controlled by its practitioners.
Massachusetts sourcing questions
- Does Massachusetts have a stem cell law that covers exosomes?
- Massachusetts has no stem cell practice statute. Chapter 27 of the Acts of 2005 created M.G.L. c. 111L, which governs embryonic stem cell research at institutions registered with the Department of Public Health, and it does not regulate services in a practice. Exosome products are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Does my Massachusetts clinic need a non-resident pharmacy or wholesale druggist license to buy exosomes?
- No. Both licenses sit with the entity that ships into the state: the non-resident pharmacy license under M.G.L. c. 112, § 39J and the wholesale druggist license under § 36B. Your practice orders against its own professional license and NPI, and ExaVeyra confirms destination licensure across its supply chain before a first order ships.
- Can my Massachusetts practice source 503A compounded peptides through ExaVeyra?
- Not at this time. Compounded formulations are prepared by our 503A pharmacy partner, a compounding pharmacy licensed by the Texas State Board of Pharmacy, and it is not currently licensed to ship compounded preparations into Massachusetts. The commonwealth requires an out-of-state pharmacy that ships drug preparations in to hold a non-resident pharmacy license under M.G.L. c. 112, § 39J, and holds sterile compounding to current USP standards under § 39G. What ExaVeyra supplies to Massachusetts practices is Kimera exosome material. Submit an inquiry and we will set out the sourcing options currently open to a Massachusetts practice.
- Does my medical spa need a clinic license in Massachusetts?
- It depends on who owns it. Under M.G.L. c. 111, §§ 51 and 52 and the Department of Public Health’s medical spa advisory, an establishment providing medical services is licensed as a clinic under 105 CMR 140.000 unless it is wholly owned and controlled by the practitioners providing those services and does not call itself a clinic, institute or dispensary. A practitioner-owned practice is still regulated by its own licensing board. Confirm your structure with Massachusetts counsel.
- What does ExaVeyra verify before opening a Massachusetts account?
- An active Massachusetts professional license checked with the relevant board, a valid NPI, and a signed professional-use acknowledgment for exosome material. Practices buying for resale also provide a Sales Tax Resale Certificate, Form ST-4.
- Who in a Massachusetts practice can handle exosome material?
- Physicians licensed by the Board of Registration in Medicine act within their scope and supervise physician assistants under § 9E. Nurse practitioners with independent practice authority under § 80E order within nursing scope; before the two-year threshold they prescribe under agreed guidelines. Registered nurses perform cosmetic procedures within Advisory Ruling 1301 to an order from a practitioner who may prescribe, without selecting the medication, device or setting. Confirm your own protocols with Massachusetts counsel.
- How should exosome material be handled on arrival?
- Check the temperature indicator included with the shipment before the vials go into storage, and move them to their storage condition promptly. If the indicator reads outside range, contact us before use rather than storing the shipment. Storage and handling conditions follow the manufacturer's handling instructions, which ship with each order, and every vial carries its lot number.
Sources
Last reviewed 11 September 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- M.G.L. c. 112, § 39J, non-resident pharmacies (accessed 10 September 2026)
- M.G.L. c. 112, § 36B, wholesale druggist licenses (accessed 10 September 2026)
- M.G.L. c. 112, § 39G, retail sterile compounding pharmacy license (accessed 10 September 2026)
- 247 CMR 7.00, wholesale druggists (Board of Registration in Pharmacy) (accessed 10 September 2026)
- 247 CMR 6.00, licensure of pharmacies (Board of Registration in Pharmacy) (accessed 10 September 2026)
- Massachusetts DPH Drug Control Program, manufacturer and distributor registration information (accessed 10 September 2026)
- M.G.L. c. 111, § 51, licensure of clinics by the Department of Public Health (accessed 10 September 2026)
- 105 CMR 140.000, licensure of clinics (accessed 10 September 2026)
- Acts of 2005, Chapter 27, An Act Enhancing Regenerative Medicine in the Commonwealth (accessed 10 September 2026)
- 830 CMR 64H.8.1, resale and exempt use certificates (Form ST-4) (accessed 10 September 2026)
- FDA Public Safety Notification on Exosome Products (accessed 10 September 2026)
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.